Targeting collagen damage for sustained in situ antimicrobial activities

Xiaoyun Mo,Suwen Zhao,Jie Zhao,Yongjie Huang,Tao Li,Yongqiao Zhu,Gang Li,Yang Li,Hong Shan
DOI: https://doi.org/10.1016/j.jconrel.2023.06.013
IF: 11.467
2023-06-24
Journal of Controlled Release
Abstract:Antimicrobial peptides (AMPs) are promising anti-infective drugs, but their use is restricted by their short-term retention at the infection site, non-targeted uptake, and adverse effects on normal tissues. Since infection often follows an injury ( e.g. , in a wound bed), directly immobilizing AMPs to the damaged collagenous matrix of the injured tissues may help overcome these limitations by transforming the extracellular matrix microenvironment of the infection site into a natural reservoir of AMPs for sustained in situ release. Here, we developed and demonstrated an AMP-delivery strategy by conjugating a dimeric construct of AMP Feleucin-K3 (Flc) and a collagen hybridizing peptide (CHP), which enabled selective and prolonged anchoring of the Flc-CHP conjugate to the damaged and denatured collagen in the infected wounds in vitro and in vivo . We found that the dimeric Flc and CHP conjugate design preserved the potent and broad-spectrum antimicrobial activities of Flc while significantly enhancing and extending its antimicrobial efficacy in vivo and facilitating tissue repair in a rat wound healing model. Because collagen damage is ubiquitous in almost all injuries and infections, our strategy of targeting collagen damage may open up new avenues for antimicrobial treatments in a range of infected tissues.
pharmacology & pharmacy,chemistry, multidisciplinary
What problem does this paper attempt to address?